FWPのチャート
FWPの企業情報
| symbol | FWP |
|---|---|
| 会社名 | Forward Pharma A/S （フォワ―ド・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187 a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications including multiple sclerosis (MS). The Company's clinical candidate FP187 is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders such as psoriasis. The Company's DMF formulation FP187 employs over two methods which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels which in turn controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187. フォワ―ド・ファ―マはデンマ―クのバイオ医薬品会社。多発性硬化症及び乾癬などの免疫疾患の治療法を開発・商品化する。免疫調節化合物のフマル酸ジメチルや誘導体に重点を置いた、遅延・持続放出性の経口医薬品の開発活動を行う。同社は2005年に設立され、コペンハ―ゲンに拠点を置く。 Forward Pharma A/S is a Danish biopharmaceutical company that commenced development in 2005 of a proprietary formulation of DMF for the treatment of inflammatory and neurological indications. The Company granted to Biogen an irrevocable license to all of its IP through the License Agreement and received from Biogen a non-refundable cash fee of $1.25 billion in February 2017, with the return of EUR 917.7 million to shareholders through a capital reduction in September 2017. The Company has the opportunity to receive royalties from Biogen on Biogen's net sales of Tecfidera® or other DMF products for multiple sclerosis outside the U.S., dependent on, among other things, a favorable outcome in Europe with respect to the Opposition Proceeding, including any appeal thereto. |
| 本社所在地 | Ostergrade 24A 1 Copenhagen DK-1100 DNK |
| 代表者氏名 | Claus Bo Svendsen Claus Bo Svendsen |
| 代表者役職名 | Chief Executive Officer |
| 電話番号 | -7543 |
| 設立年月日 | 38534 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 5人 |
| url | www.forward-pharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fwp |
| adr_tso | 11484285 |
| EBITDA | EBITDA（百万ドル） -33.82800 |
| 終値（lastsale） | 2.44 |
| 時価総額（marketcap） | 28021655.4 |
| 時価総額 | 時価総額（百万ドル） 100.03010 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 10.76910 |
| 当期純利益 | 当期純利益（百万ドル） -29.41300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Forward Pharma A/S revenues decreased from $1.25B to $0K. Net loss totaled $5.3M vs. income of $941.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects General and Administrative costs increase of 31% to $5.8M (expense) Interest Income decrease from $160K (income) to $0K. |
FWPのテクニカル分析
FWPのニュース
Forward Pharma GAAP EPS of -$0.02 2022/04/11 04:23:51 Seeking Alpha
Forward Pharma press release (FWP): FY GAAP EPS of -$0.02.At December 31, 2021, the Group had cash and cash equivalents of $70.8M and working capital of $70.8M
Forward Pharma granted Australian patent linked to multiple sclerosis therapy 2021/12/23 16:49:28 Seeking Alpha
Short Interest in Forward Pharma A/S (NASDAQ:FWP) Decreases By 31.0% 2021/12/20 00:26:41 Dakota Financial News
Forward Pharma A/S (NASDAQ:FWP) was the recipient of a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 73,100 shares, a drop of 31.0% from the November 15th total of 105,900 shares. Approximately 1.1% of the shares of the company are short sold. Based on []
Forward Pharma A/S (NASDAQ:FWP) Sees Large Growth in Short Interest 2021/12/04 09:54:43 Dakota Financial News
Forward Pharma A/S (NASDAQ:FWP) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 105,900 shares, a growth of 39.5% from the October 31st total of 75,900 shares. Currently, 1.6% of the companys stock are sold short. Based on an average []
Short Interest in Forward Pharma A/S (NASDAQ:FWP) Declines By 29.1% 2021/11/20 16:50:45 Transcript Daily
Forward Pharma A/S (NASDAQ:FWP) saw a large drop in short interest in October. As of October 29th, there was short interest totalling 75,900 shares, a drop of 29.1% from the October 14th total of 107,000 shares. Based on an average daily trading volume, of 133,500 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.1% []
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres'' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO 2021/07/22 12:18:01 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) Bio-Techne Corporation (NASDAQ: TECH ) BioNTech SE (NASDAQ: BNTX ) Cassava Sciences, Inc. (NASDAQ: SAVA ) Cortexyme, Inc. (NASDAQ: CRTX ) (announced new preclinical data for its lead drug candidate atuzaginstat in periodontal disease) Intuitive Surgical, Inc. (NASDAQ: ISRG ) (reacted to better-than-expected second-quarter results) Forward Pharma A/S (NASDAQ: FWP ) Legend Biotech Corporation (NASDAQ: LEGN ) NeuroMetrix, Inc. (NASDAQ: NURO ) Protagonist Therapeutics, Inc. (NASDAQ: PTGX ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 21) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Cyteir Therapeutics, Inc. (NASDAQ: CYT ) Elevation Oncology, Inc. (NASDAQ: ELEV ) Ensysce Biosciences, Inc. (NASDAQ: ENSC ) ERYTECH Pharma S.A. (NASDAQ: ERYP ) HCW Biologics Inc. (NASDAQ: HCWB ) (IPOed Tuesday) Lumos Pharma, Inc. (NASDAQ: LUMO ) ( signaled a delay in clinical trials of its treatment for pediatric growth deficiency) Medicenna Therapeutics Corp. (NASDAQ: MDNA ) Nautilus Biotechnology, Inc. (NASDAQ: NAUT ) OptiNose, Inc. (NASDAQ: OPTN ) POINT Biopharma Global Inc. (NASDAQ: PNT ) Regencell Bioscience Holdings Limited (NASDAQ: RGC ) (IPOed Friday) VectivBio Holding AG (NASDAQ: VECT ) Yumanity Therapeutics, Inc. (NASDAQ: YMTX ) Stocks In Focus Erytech Plans Regulatory Submission For Eryaspase In Blood Cancer Following Positive Pre-BLA Meeting Erytech said it intends to move forward toward the submission of a biologic license application to the U.S.
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street 2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
Forward Pharma A/S - ADR Shares Climb 100.0% Past Previous 52-Week High - Market Mover 2021/07/17 02:07:44 Kwhen Finance
Forward Pharma A/S - ADR (FWP) shares closed 100.0% lower than its previous 52 week high, giving the company a market cap of $76M. The stock is currently up 57.0% year-to-date, up 76.9% over the past 12 months, and down 57.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 11.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1051.5% The company's stock price performance over the past 12 months beats the peer average by 833.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Forward Pharma A/S - ADR Shares Close the Week 33.3% Higher - Weekly Wrap 2021/07/17 02:07:44 Kwhen Finance
Forward Pharma A/S - ADR (FWP) shares closed this week 33.3% higher than it did at the end of last week. The stock is currently up 57.0% year-to-date, up 76.9% over the past 12 months, and down 57.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Shares traded as high as $11.50 and as low as $8.28 this week.Trading volume this week was 38.5% lower than the 10-day average and 11.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price beats the S&P 500 Index this week, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1051.5% The company's stock price performance over the past 12 months beats the peer average by 833.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Forward Pharma A/S - ADR Shares Climb 100.0% Past Previous 52-Week High - Market Mover 2021/07/17 01:43:36 Kwhen Finance
Forward Pharma A/S - ADR (FWP) shares closed 100.0% lower than its previous 52 week high, giving the company a market cap of $76M. The stock is currently up 57.0% year-to-date, up 76.9% over the past 12 months, and down 57.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 11.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1051.5% The company's stock price performance over the past 12 months beats the peer average by 833.5%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The Daily Biotech Pulse: ScPharma''s Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues 2021/07/14 11:48:12 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical Holding Company Ltd. . (NYSE: BHVN ) AngioDynamics, Inc. (NASDAQ: ANGO ) (reacted to its fiscal-year 2021 fourth-quarter results) Bicycle Therapeutics plc (NASDAQ: BCYC ) ( announced Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) exercised option to use its tissue-targeted delivery of oligonucleotide therapeutics tech) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Forward Pharma A/S (NASDAQ: FWP ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) PLx Pharma Inc. (NASDAQ: PLXP ) (announced availability of FDA-approved liquid-filled aspirin capsules in Walmart Inc. (NYSE: WMT ) stores) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) Unicycive Therapeutics, Inc. (NASDAQ: UNCY ) (IPOed Tuesday) Zoetis Inc. (NYSE: ZTS ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 13) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc.